Miele, E;
Benninga, MA;
Broekaert, I;
Dolinsek, J;
Mas, E;
Orel, R;
Pienar, C;
... Thapar, N; + view all
(2020)
Safety of Thiopurine Use in Paediatric Gastrointestinal Disease.
Journal of Pediatric Gastroenterology and Nutrition
, 71
(2)
pp. 156-162.
10.1097/MPG.0000000000002802.
Preview |
Text
Safety_of_Thiopurine_Use_in_Paediatric.96032.pdf - Accepted Version Download (484kB) | Preview |
Abstract
Thiopurines, alone or in combination with other agents, have a pivotal role in the treatment of specific gastrointestinal and hepatological disorders. In inflammatory bowel disease and autoimmune hepatitis thiopurines have proven their value as steroid sparing agents for the maintenance of remission and may be considered for preventing postoperative Crohn's disease recurrence where there is moderate risk of this occuring. Their use with infliximab therapy reduces antibody formation and increases biologic drug levels. However, the routine clinical use of thiopurines has been questioned due to a number of potential adverse effects. The aim of this paper is to provide information regarding the use, and in particular, safety of these agents in clinical practice in the light of such potentially severe, albeit rare, effects.
Archive Staff Only
 |
View Item |
